Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Renalytix AI ( (GB:RENX) ) just unveiled an update.
Renalytix plc announced recent share dealings involving its directors, highlighting notable transactions by key leadership figures. Christopher Mills, Non-Executive Chairman, sold a portion of his shares, while CEO James McCullough, President Howard Doran, and Executive Chairman Julian Baines increased their stakes in the company through significant share purchases. These transactions suggest ongoing confidence in Renalytix’s strategic direction and market positioning, potentially signaling positive implications for stakeholders and the company’s future growth prospects.
More about Renalytix AI
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics and laboratory services company, recognized as a leader in bioprognosis™ for kidney health. The company focuses on optimizing clinical management of kidney disease to improve patient outcomes and advance value-based care. Its flagship product, KidneyIntelX, is designed for risk assessment of rapid decline in kidney function among adults with type 2 diabetes and early-stage chronic kidney disease.
YTD Price Performance: -46.67%
Average Trading Volume: 4,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.97M
For an in-depth examination of RENX stock, go to TipRanks’ Stock Analysis page.
